Synterica, Inc.

Biotechnology ResearchUnited States2-10 Employees

Synterica makes oral therapeutics for treatment of enteric disease with a goal of promoting gastrointestinal health.  Our products directly target pathogenic bacteria and their toxins in the gut without harming beneficial bacteria.  

While antibiotics have saved many lives, we live in an era when bacterial resistance to antibiotics has become a problem. In addition to the problems of resistance, antibiotics can disrupt the healthy balance of gut microflora allowing pathogenic bacteria to flourish and directly contribute to disease. These problems drive the need for new and innovative therapeutics.

Synterica is developing innovative therapeutics that directly bind to and eliminate selected pathogenic bacteria and their toxins in the gut.  We do this by combining specific targeting and neutralizing agents with natural packaging material made from living ingestible organisms that also serve as the means for large-scale production.

Our first target is an oral therapeutic to neutralize the toxins secreted by Clostridium difficile.  The two toxins are responsible for the devastating effects of the infection and neutralizing them is expected to reduce pathogenesis of the disease.

Sign up for free to view info

Email Format Employee directory